Stifel Downgrades Neoleukin Therapeutics (NLTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
November 14, 2022 4:03 PM EST-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 --
SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo... More
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
November 14, 2022 4:03 PM EST-- Development of NL-201 to be discontinued for strategic reasons --
-- Company to focus on next-generation de novo proteins and core technology --
-- Company restructuring to extend cash runway into the second half of 2025 --
SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de... More
